Wolverine Asset Management’s Adicet Bio ACET Stock Holding History

Wolverine Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-179	Closed	-$191K	–	1369
2018 Q1	$191K	Buy	+179	New	+$328K	﹤0.01%	1157

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Wolverine Asset Management's ACET Position: Q2 2018 in Review

Wolverine Asset Management sold out of Adicet Bio (ACET) in Q2 2018, closing a stake of 179 shares — an estimated $191K sold.

Wolverine Asset Management first reported a position in ACET in Q1 2018 and held it in 1 quarter. The position peaked at $191K in Q1 2018. 45 funds tracked by Wall St. Rank hold ACET as of Q2 2018.

Wolverine Asset Management reported no remaining Adicet Bio position as of Q2 2018 after selling out during the quarter.
Wolverine Asset Management sold 179 Adicet Bio shares in Q2 2018, an estimated $191K.
Wolverine Asset Management first reported a position in Adicet Bio in Q1 2018 and held it in 1 quarter.
Wolverine Asset Management's Adicet Bio position peaked at $191K in Q1 2018.
45 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2018.

Based on Wolverine Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.